Creative Medical Technology (NASDAQ:CELZ) Posts Quarterly Earnings Results, Misses Expectations By $0.43 EPS

Creative Medical Technology (NASDAQ:CELZ) posted its quarterly earnings data on Friday. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.43), FiscalAI reports. The firm had revenue of $0.00 million for the quarter.

Creative Medical Technology Stock Performance

CELZ opened at $1.84 on Friday. Creative Medical Technology has a one year low of $1.50 and a one year high of $6.25. The stock has a market capitalization of $4.75 million, a P/E ratio of -0.63 and a beta of 2.09. The business’s 50-day simple moving average is $1.93 and its 200-day simple moving average is $2.62.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Creative Medical Technology in a research report on Monday, December 29th. Wall Street Zen lowered shares of Creative Medical Technology from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Creative Medical Technology currently has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC acquired a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned about 1.17% of Creative Medical Technology as of its most recent filing with the SEC. Hedge funds and other institutional investors own 1.42% of the company’s stock.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.